Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

January 5, 2012

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced the launch of Mucosta ophthalmic suspension UD 2% for patients with dry eye diagnosed on January 5, 2012 in Japan.

Latest Pharmaceutical Business related News Releases

30 SEP 2024

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^® hematological malignancies gene panel test approved in Japan -

24 SEP 2024

Otsuka Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

24 SEP 2024

Otsuka Receives Approval in Japan for Lupkynis^® as a Treatment for Lupus Nephritis

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Mucosta® ophthalmic suspension UD2% releases on January 5, 2012

HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -

Otsuka Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^® hematological malignancies gene panel test approved in Japan -

Otsuka Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

Otsuka Receives Approval in Japan for Lupkynis^® as a Treatment for Lupus Nephritis